• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Bracco strikes Chinese partnership

Article

The Bracco Group has entered into a joint venture with Sine Pharmaceutical of Shanghai for the production and marketing in China of diagnostic contrast media. The partnership will serve as the springboard for launching this month in China two new

The Bracco Group has entered into a joint venture with Sine Pharmaceutical of Shanghai for the production and marketing in China of diagnostic contrast media. The partnership will serve as the springboard for launching this month in China two new contrast media produced by the Bracco Group, one for MR, the other for ultrasound. Demand for in vivo injectible contrast media in China is growing at more than 20% annually, according to Bracco. The Italian company owns 70% of the new Bracco-Sine joint venture. It has been commercially active in China for about 15 years. A priority of the Bracco Group's Chinese operations is to train local hospital staff and to help consolidate academic ties between Italy and China.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.